Jin Rong Jie·2025-08-22 03:58Core Viewpoint - 康希诺生物's stock surged over 8% following the release of its half-year performance report, indicating positive market sentiment towards the company's financial results and growth prospects [1] Financial Performance - The company reported a revenue of approximately 374 million RMB, representing a year-on-year increase of 31.1% [1] - The net loss attributable to the owners narrowed to 13.485 million RMB, a significant reduction of 94.02% compared to the previous year [1] Product Development - 康希诺生物 continues to advance the commercialization of its meningococcal conjugate vaccine, with successful penetration into the mid-to-high-end vaccine market in China [1] - Sales revenue from the meningococcal conjugate vaccine reached approximately 364 million RMB, marking a year-on-year growth of 38.4%, contributing to the company's stable revenue growth [1]